Bio-Electroceutical Science & Technology (B.E.S.T.)
No branch of science has grown more rapidly or produced more dramatic results than biomedicine: the biggest excitement swirled around the potential for the ultimate solution for personal medicine: an unlimited supply of replacement parts cloned from the patient’s own cells.
According to Harold Varmus, a Nobel Prize winner and the former NIH director: "The development of cell lines that may produce almost every tissue of the human body is an unprecedented scientific breakthrough. It is not too unrealistic to say that this research has the potential to revolutionize the practice of medicine and improve the quality of life."
Mission Statement
- Assess the potential therapeutic value of discoveries emanating from advanced research in the life sciences and understand ways to accelerate these discoveries into therapeutics, and medical devices.
- Determine the most promising strategy for science-based organizations, including novel ways for expanding access to crucial investment funds and securities offerings.
- Develop approaches to novel therapeutics, including investment in neglected diseases, AI, nano technology, new biologics and medical devices.
- Establish laboratories, worldwide partnerships and humanitarian missions.
Here at BEST Biotecnica, are explorers on a quest for the secrets which unlocks the mysteries of Cancer, Heart disease and Neurological maladies. The three great harbingers of death and suffering of our age.
As a non-profit bioscience company focused on accelerated development of break-through biologics and advanced medical devices, we have developed a new type of business model which thinks outside the archaic big pharma paradigm, which searches for the next billion-dollar block buster.
We view cancer and heart disease as a global health threat which kills countless millions and leaves many more millions suffering and dying in perpetuity.
Where are the big pharma companies ready to throw their weight into actually helping these billions of dying souls?
We need to take our medical mission to the world beyond the limits of western medicine and repressive regulatory authorities.
It now costs over $2 billion dollars and 10 long years in the regulatory pipeline to develop a single drug!
The world needs solutions now, not someday.
According to the eminent interventional cardiologist Dr. Devi Shetty, “A cure is not a solution, if it is not affordable”!
By developing cellular proliferation disruption bioreactors which may slow or even prevent breast cancer, we are exploring the cellular and molecular mechanisms underlying the development of all breast cancers as we seek novel new therapeutic strategies.
This is a major breakthrough involving an entirely new and formally undiscovered branch of cancer research.
“In women’s regenerative and preventative medicine, these discoveries were like landing on the moon”.
Dr. Julia Polak Dame Commander of the British Empire
Also, more than ten long years of R&D were spent on the quest for a cardio tissue engineering therapeutic, capable of regenerating and restoring the functions of aged and diseased hearts.
CardioMatrex ® The Future of Cardio Therapeutics
CardioMatrex Tissue Engineering Biologic
Along the way we discovered another new disruptive technology: the neural reanimation bioreactor for cognitive enhancement, which is in phase I and phase II clinical studies with former NFL football players who have sustained brain injuries, and face uncurable deadly brain disease.
New Video: 87 Deceased NFL Players Test Positive for Brain Disease
CTE: Chronic Traumatic Encephalopathy
Doctors weigh in after study finds brain disease in 99% of ex-NFL players
Single-photon emission computed tomography (SPECT) brain imaging, provides 1000’s of datapoints to create 3D pictures of the brain in 120 regions delivering state-of-the-art brain imaging. By comparing before and after brain scans the physicians at St John’s Hospital in Santa Monica are ready to put our powerful neural reanimation bioreactor to the test.
Big pharma has spent 100’s of billions of dollars in abysmal FDA/EMA studies that have crashed and burned on the quest of a break-through neuro biologic. We propose that we may have a much better solution.
We suggest that perhaps we have discovered another highly affectatious approach, and will be sharing our findings with the National Science Foundation while planning a neuroscience convention at the Salk Institute in La Jolla, California.